Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Other Accumulated Expenses (2019 - 2025)

Opus Genetics has reported Other Accumulated Expenses over the past 7 years, most recently at $268000.0 for Q3 2025.

  • Quarterly Other Accumulated Expenses rose 325.4% to $268000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $268000.0 through Sep 2025, up 325.4% year-over-year, with the annual reading at $606000.0 for FY2024, 753.52% up from the prior year.
  • Other Accumulated Expenses was $268000.0 for Q3 2025 at Opus Genetics, up from $265000.0 in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $606000.0 in Q4 2024 and troughed at $8000.0 in Q3 2021.
  • The 5-year median for Other Accumulated Expenses is $74000.0 (2022), against an average of $129789.5.
  • Year-over-year, Other Accumulated Expenses surged 825.0% in 2022 and then crashed 57.49% in 2023.
  • A 5-year view of Other Accumulated Expenses shows it stood at $80000.0 in 2021, then skyrocketed by 108.75% to $167000.0 in 2022, then crashed by 57.49% to $71000.0 in 2023, then skyrocketed by 753.52% to $606000.0 in 2024, then plummeted by 55.78% to $268000.0 in 2025.
  • Per Business Quant, the three most recent readings for IRD's Other Accumulated Expenses are $268000.0 (Q3 2025), $265000.0 (Q2 2025), and $380000.0 (Q1 2025).